Immunohistochemistry (IHC) is a lab technique that uses antibodies to detect specific proteins in tissue samples. It’s one of the most widely used tools in pathology, helping doctors identify what type of cells are present in a biopsy, determine where a cancer originated, and guide treatment decisions based on which proteins a tumor does or doesn’t produce. If you’ve had a biopsy and your pathology report mentions IHC, it means your tissue was tested this way to get a more precise diagnosis.
How the Technique Works
The core principle is straightforward: antibodies lock onto specific proteins the way a key fits a lock. In the lab, pathologists apply specially designed antibodies to a thin slice of tissue mounted on a glass slide. If the target protein is present in that tissue, the antibody binds to it. That binding event is then made visible under a microscope using either a color-producing chemical reaction or a fluorescent tag attached to the antibody.
There are two main approaches. In the direct method, the antibody that binds the target protein already carries a visible label. In the indirect method, a second antibody is applied on top of the first one, and this second antibody carries the label. The indirect method is far more common because layering antibodies amplifies the signal, making faint proteins easier to detect.
From Biopsy to Slide
Before any antibody touches the tissue, the sample goes through several preparation steps. First, the tissue is preserved (fixed) in a chemical solution, most commonly formalin, to keep its structure intact. It’s then embedded in paraffin wax and sliced into sections thin enough for light to pass through, typically just a few micrometers thick. These slices are placed on glass slides.
There’s a catch: formalin preservation, while excellent at maintaining tissue architecture, can mask the very proteins the antibodies need to find. Chemical cross-links form around those proteins and hide the binding sites. To undo this, labs use a step called antigen retrieval. The most common method involves heating the tissue in a buffer solution at or above 100°C for several minutes up to half an hour. This heat-based approach was a breakthrough that dramatically expanded the number of proteins detectable in preserved tissue. An older approach uses digestive enzymes to break apart the cross-links, though this is harder to control and risks damaging the tissue.
After retrieval, the slide is treated with a blocking solution to prevent antibodies from sticking to the wrong things. Then the primary antibody is applied, followed by the secondary antibody with its label, washing steps to remove anything that didn’t bind, and finally mounting under a coverslip for examination.
Making the Invisible Visible
The label attached to the antibody determines what the pathologist sees. Chromogenic labels produce a permanent color stain visible under a standard light microscope. The most common chromogen, DAB, produces a brown color at the site where the target protein sits. Other chromogens create red, purple, or green stains. Chromogenic IHC is the workhorse of diagnostic pathology because the stained slides are stable, easy to store, and can be reviewed without specialized equipment.
Fluorescent labels work differently. They absorb light at one wavelength and emit it at another, glowing under a fluorescence microscope. Common fluorescent dyes produce green or magenta signals. Newer fluorescent compounds developed over the past decade resist fading better than their predecessors, which makes them more practical for clinical use. Fluorescence is especially useful when researchers or pathologists need to visualize multiple proteins on the same slide, since different dyes glow in distinct colors that can be distinguished from one another.
Monoclonal vs. Polyclonal Antibodies
Not all antibodies used in IHC are the same. Monoclonal antibodies come from a single cell line and recognize only one precise spot on a protein. This makes them extremely specific, which is valuable when you need to distinguish between closely related proteins or when a definitive yes-or-no answer matters for diagnosis.
Polyclonal antibodies come from multiple cell lines and recognize several different spots on the same protein. They cast a wider net, which generally produces a stronger signal because more antibodies can latch on at once. This broader recognition is useful when the target protein may be partially degraded or when maximum sensitivity is the priority. Both types are used routinely, and the choice depends on what the pathologist is looking for.
Cancer Diagnosis and Classification
IHC is indispensable in cancer pathology. When a pathologist looks at a tumor under the microscope, the cells sometimes look so abnormal that it’s unclear what tissue they came from. This is especially common with metastatic cancers, where a tumor found in one organ actually originated somewhere else. By testing for proteins characteristic of specific tissues, IHC can pinpoint the cancer’s origin. For example, prostate biopsies are routinely stained with antibodies that highlight basal cells (a normal cell layer) and a protein found in prostate cancer cells. The pattern of staining helps confirm whether cancer is present and how far it has progressed.
Beyond identifying tumor type, IHC also classifies cancers into subtypes that behave differently and respond to different treatments. This subtyping has become central to how oncologists choose therapy.
Guiding Treatment Decisions
Some of the most consequential IHC tests are those that determine whether a breast cancer will respond to specific therapies. Three protein markers tested by IHC shape nearly every breast cancer treatment plan:
- Estrogen receptor (ER) and progesterone receptor (PR): If at least 1% of tumor cells stain positive for these hormone receptors, the cancer is classified as hormone receptor-positive and is likely to respond to hormone-blocking therapies. About two-thirds of breast cancers fall into this category.
- HER2: This protein, when overproduced by cancer cells, drives aggressive growth. IHC testing identifies HER2-positive tumors, which can then be treated with targeted therapies designed to block that protein. Guidelines developed by major oncology and pathology organizations standardize how this testing is performed and interpreted.
- Ki-67: This protein indicates how quickly cells are dividing. A high percentage of Ki-67-positive cells suggests a fast-growing tumor, which can influence decisions about the intensity of treatment.
IHC has almost completely replaced older biochemical methods for these tests because it integrates easily into standard pathology workflows, works on the same preserved tissue used for diagnosis, and doesn’t require separate fresh tissue samples.
How Pathologists Score the Results
IHC results aren’t simply positive or negative. Pathologists evaluate two things: how intensely the tissue stains and what proportion of cells are stained. Staining intensity is graded on a four-point scale from 0 (no staining) to 3 (strong staining). The percentage of cells that stain at each intensity level is also recorded.
Several standardized scoring systems combine these two factors into a single number. The H-score, Allred score, and Immunoreactive score are considered gold standards in the field. Each uses slightly different formulas, but they all aim to convert a subjective visual impression into semi-quantitative data that can be compared across patients and institutions. Digital image analysis tools are increasingly used alongside manual scoring to reduce variability between different pathologists reading the same slide.
Turnaround Time for Patients
If you’re waiting on biopsy results that include IHC testing, the typical timeline is a few days. Standard biopsies take two to three days to process and read, and IHC staining adds one to two additional days on top of that. So from the time your tissue reaches the lab, you can generally expect results within about a week, though complex cases requiring multiple rounds of staining can take longer.
Multiplex Staining
Traditional IHC labels only one protein per tissue section. If a pathologist wants to test for five proteins, that requires five separate slides cut from the same tissue block. This is a real limitation when tissue is scarce, as it often is with small needle biopsies or rare donor samples.
Newer multiplex techniques allow simultaneous detection of multiple proteins on a single slide. Each protein gets a distinct color, and specialized software maps where different cell types sit relative to one another. This matters because it reveals not just which proteins are present, but how different cell types interact within the tissue. Recent studies have shown that multiplex IHC can predict whether patients will respond to certain immunotherapy drugs more accurately than single-marker testing alone. These techniques are moving from research settings into routine clinical use, particularly in the growing field of cancer immunotherapy where understanding the relationship between tumor cells and immune cells is critical to choosing the right treatment.